BMJ Open

# Efficacy and safety of high-voltage versus standard-voltage pulsed radiofrequency ablation for patients with neuropathic pain: protocol for a systematic review and meta-analysis

Yitong Jia ,[1] Zheng Wang ,[2] Yanhui Ma,[1] Tengteng Wang,[3] Kunpeng Feng,[1] Guang Feng,[1] Tianlong Wang[4]

**To cite:** Jia Y, Wang Z, Ma Y, *et al*. Efficacy and safety of high-voltage versus standard-voltage pulsed radiofrequency ablation for patients with neuropathic pain: protocol for a systematic review and meta-analysis. *BMJ Open* 2022;**12**:e063385. doi:10.1136/bmjopen-2022-063385

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/bmjopen-2022-063385).

YJ, ZW and YM are joint first authors.

Received 30 March 2022
Accepted 21 June 2022



For numbered affiliations see end of article.

**Correspondence to**
Professor Tianlong Wang;
w_tl5595@hotmail.com

## ABSTRACT

**Introduction** Pulsed radiofrequency (PRF) ablation is commonly used for the treatment of neuropathic pain (NP). However, it is unclear whether increasing the output voltage of PRF can safely improve its efficacy. This study aims to compare the efficacy and safety of high-voltage PRF ablation and standard-voltage PRF ablation for the treatment of patients with NP.

**Methods and analysis** We will search PubMed/MEDLINE, EMBASE, Web of Science, the Cochrane Library, conference proceedings for relevant abstracts, clinical trials registers (ClinicalTrials.gov) and the WHO's International Clinical Trial Registry Platform (from the date of inception until 15 March 2022). Only randomised controlled trials will be included. Two reviewers (YJ and GF) will independently perform study screening and selection, data extraction, risk-of-bias assessment and quality-of-evidence assessment. The primary outcome of this meta-analysis will be the efficiency rate in patients with NP. The secondary outcomes will include numeric rating scale score, visual analogue scale score, time to take effect, rescue drug dosage, quality of life using the health questionnaire (SF-36) and the incidence of adverse events. Meta-analyses will be conducted using standard meta-analysis software (RevMan V.5.3, The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark).

**Ethics and dissemination** The requirement for ethical approval was waived as our systematic review will be based on the published literature. The results of this study will be submitted to a peer-reviewed journal.

**PROSPERO registration number** CRD42022297804.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ To the best of our knowledge, this will be the first systematic review and meta-analysis to evaluate the efficacy and safety of high-voltage pulsed radiofrequency ablation for the treatment of patients with neuropathic pain. To provide unbiased information, only randomised controlled trials will be included.
⇒ The study findings will provide comprehensive information for future study designs in terms of interventional treatment of neuropathic pain.
⇒ The accuracy of our research conclusions might be subjected to language limitations as only studies published in English will be included.

## INTRODUCTION

Neuropathic pain (NP) is a common chronic pain condition caused by lesions or diseases affecting the somatosensory nervous system, including trigeminal neuralgia (TN), peripheral nerve injury pain, painful polyneuropathy, postherpetic neuralgia and central poststroke pain.[1] Epidemiological data have reported that the global prevalence of NP is approximately 6.9%–10%.[2] NP is a refractory pain syndrome with a long duration of occurrence, frequent recurrent attacks and poor response to traditional analgesics. Most patients with NP suffer from ongoing or intermittent spontaneous pain accompanied by burning, pricking and squeezing sensations, and have a poor quality of life (QoL).[3] Therefore, finding an effective treatment option for NP and improving patients' QoL is of great importance.

In recent years, pulsed radiofrequency (PRF) ablation, a new type of neuromodulation technique, has been successfully applied in the treatment of NP.[4–9] Different from continuous radiofrequency, which produces heat by friction and vibration, leading to thermocoagulation, denaturation and necrosis of the target tissue,[10 11] PRF provides pulsed energy waves followed by a 480 ms heat dissipation interval, and the temperature does not exceed 42°C.[12–14] PRF treatment exerts its effect via the modulation of nerve function, which is a result of the electric field effect and not the impedance of pain signal transduction;[15 16] thus, PRF ablation is a

non-destructive technique that can be repeatedly applied without causing nerve tissue damage.

The standard proposed PRF parameters are set as follows: an output voltage of 45 V, temperature of 42°C, pulse frequency of 2 Hz, output frequency of 500 kHz, continuous current action of 20 ms and intermission period of 480 ms. Recently, scholars have attempted to treat patients with NP using high-voltage PRF ablation. Teixeira and Sluijter first reported that a high-voltage PRF ablation of 60 V used to treat patients with discogenic pain attained satisfactory efficacy that lasted over 3 months.[17] In 2013, Luo *et al* found that the postoperative numeric rating scale (NRS) score had a significant negative correlation with the output voltage of PRF.[18] Afterwards, Luo *et al* compared the efficacy of high-voltage PRF with standard-voltage PRF for idiopathic TN patients who responded poorly to oral carbamazepine or nerve blockade by steroid, and the results revealed the 1 year effective rate of high-voltage PRF (69%) was significantly higher than that in the standard-voltage PRF treatment(19%) (p=0.000).[19]Additionally, they compared the efficacy of high-voltage PRF and standard voltage PRF for refractory neuralgia infraorbital nerve therapy, and reported that high-voltage PRF ablation could achieve higher response rates at 1 month, 3 months, 6 months and 1 year post procedure.[20] Jia *et al* retrospectively analysed the medical data of patients with idiopathic TN undergoing PRF. The study found that for patients who did not respond to the first PRF treatment and underwent the second PRF treatment, a higher dose of output voltage than the initial one could achieve improved analgesic effect.[21–23]

However, the number of patients who experienced mild numbness postoperatively was greater in the high-voltage group (27%) than in the standard-voltage group (13%).[20] In addition, a randomised controlled trial (RCT) conducted by Wan *et al* showed that the scores were significantly lower in the high-voltage group than in the standard-voltage group at 3 and 6 months; however, no significant difference was observed at 1 month after treatment.[24] A study by Wan *et al* revealed that the incidence of ecchymoses in the high-voltage group (19.2%) was higher than that in the standard-voltage group (12.1%). As a result, further analysis is required to determine whether the efficacy of high-voltage PRF ablation at different timepoints is superior to that of standard-voltage PRF ablation, and whether high-voltage PRF ablation is a safe treatment method for NP.

The primary objectives of this study will be to compare the efficacy and safety of high-voltage PRF ablation and standard-voltage PRF ablation for the treatment of NP at different timepoints postoperatively through a systematic review and meta-analysis of RCTs.

## METHODS

This protocol was developed according to the reporting guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols statement[25] (checklist in online supplemental file 1). Our systematic review will be conducted in accordance with the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions.[26] Any amendments made to this protocol and the whole review process will be updated in a timely manner on the PROSPERO registration and the final manuscript.

### Criteria for considering eligible studies

#### Types of studies

Only RCTs will be included. All studies must be published in English. Experimental animal studies will be excluded.

#### Participants

Patients with NP conditions recognised and defined by the International Association for the Study of Pain[27] will be included. NP is initiated or caused by a primary lesion or dysfunction of the nervous system. Studies regarding diabetic neuropathy, complex regional pain syndrome type 1, low back pain without radicular pain and postsurgical pain will be excluded.

#### Interventions and comparators

We will examine trials investigating high-voltage PRF treatment for patients with NP. The high-voltage PRF treatment will be set to the manual pulse mode: the initial voltage will be 40 or 45 V, and the output voltage will then be gradually increased to the highest voltage the patient can tolerate (temperature control below 50°C). The comparator will be the standard PRF treatment.

#### Outcome measures

The primary outcome of this meta-analysis is the efficiency rate in patients with NP. The predefined timepoints for the efficiency rate will be 1 month, 3 months and 6 months after the procedure. Additionally, 1-year or 2-year timepoint will also be considered. Treatment efficiency recurrence is defined as a pain reduction of greater than 50% after treatment compared with pre surgery. Secondary outcomes will include (NRS) or visual analogue scale (VAS) score, time to take effect, rescue drug dosage, QoL determined using a health questionnaire (SF-36)[28] at 1 month, 3 months and 6 months postoperatively, and incidence of adverse events (AEs).

### Information sources and search strategy

A computer-based search strategy will be designed by an experienced librarian and revised by another expert librarian according to the Peer Review of Electronic Search Strategies checklist.[29] The primary source of the literature will be the following major electronic databases: PubMed/MEDLINE, EMBASE, Web of Science and the Cochrane Library (from the date of inception until 15 March 2022). The secondary source of potentially relevant research includes conference proceedings for relevant abstracts, clinical trials registers (ClinicalTrials.gov) and the WHO's International Clinical Trial Registry Platform to identify ongoing studies. The search will encompass a broad range of terms and keywords

related to 'high-voltage', 'pulsed radiofrequency', 'neuropathic pain' and 'RCT'. The detailed search strategy is presented in online supplemental file 2.

## Data selection and analysis

### Study selection

We will use the Population, Intervention, Comparison, Outcome model[30] to determine the specific criteria for selecting studies. Two reviewers (YJ and GF) will independently screen and select the relevant studies. During the initial screening, reviewers will determine whether the study could be included by screening the titles and abstracts retrieved via database search. We will screen the full texts retained from the initial selection of articles to include studies that meet the eligibility criteria. Disagreements between the two reviewers will be resolved by a third reviewer (TeW). If several studies present data from the same study population or multiple publications from the same study are published in chronological order, the study with the most direct interventions or the largest sample size will be selected. The same methods will be used for citation, reference screening and selection, as well as for protocols registered in clinical trial registries.

## Data extraction

A standardised electronic form for data extraction will be created by ZW. Two reviewers (YJ and GF) will independently extract the following data: study characteristics (eg, name of the first author, year of publication, type of study, sample size), population characteristics (eg, age, gender, disease duration, medical history, preoperative pain intensity and follow-up period) and outcome data (eg, primary and secondary outcomes and any AEs caused by PRF treatment). Similarly, a third reviewer will be required to resolve any discrepancies. We will attempt to contact the study authors by email or post for further information in case of any ambiguity or insufficient information. Table 1 presents the characteristics of the studies that will be included.

## Assessment of risk-of-bias and quality-of-evidence assessment

Two reviewers (YJ and GF) will independently assess the risk of bias (RoB) and a third reviewer (ZW) will resolve discrepancies. The RoB of RCTs will be assessed according to items in the Cochrane Collaboration's tool.[26]

We will evaluate the overall quality of the body of evidence in accordance with the Grading of Recommendations Assessment, Development and Evaluation methodology,[31] which examines study design, RoB, inconsistency, indirectness and imprecision. Accordingly, quality of evidence will be rated as high, moderate, low or very low.

## Data synthesis and analysis

Meta-analyses will be conducted using the standard meta-analysis software (RevMan V.5.3, The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark). We will compute standardised mean differences and 95% CIs for continuous outcomes and risk ratios with 95% CI for binary outcomes. A two-tailed p value<0.05 will be considered statistically significant. We will assess the intervention effects between high-voltage PRF and standard-voltage PRF using preintervention to postintervention changes. When the data in the literature are expressed as median values and quartiles, we will use mathematical operations to transform them into mean and SD.[32 33] Additionally, we will use forest plots to visualise pooled estimates and the extent of heterogeneity among studies. Heterogeneity will be assessed using the $I^2$ statistic. $I^2$>50% is an indication of substantial heterogeneity, and in such cases the random effects model will be used to analyse the outcomes; otherwise, a fixed-effect model will be applied. If heterogeneity is observed, we will perform subgroup analysis according to prespecified variables, such as study design, intervention characteristics or RoB. The sources of heterogeneity will be explored using sensitivity analysis. A funnel plot[34] or Egger test[35] will be used to assess publication bias.

## Patient and public involvement

Since our study is a systematic review based on published literature, no patients will be involved.

# DISCUSSION

Our study aims to compare the efficacy and safety of high-voltage PRF ablation and standard-voltage PRF ablation

**Table 1** Main characteristics of RCTs comparing the efficacy and safety of high-voltage PRF and standard-voltage PRF for the treatment of NP

| Study ID | Sample size | Types of neuropathic pain | Setting | Duration | Number of female (%)/ male (%) patients | Age (years) | Preoperative pain (VAS/ NRS) | Preoperative QoL | Postoperative pain (VAS/ NRS) | Postoperative QoL | Complications |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | | | | | | | | | | | |
| B | | | | | | | | | | | |
| C | | | | | | | | | | | |
| ..... | | | | | | | | | | | |

NP, neuropathic pain; NRS, numeric rating scale; PRF, pulsed radiofrequency; QoL, quality of life; RCT, randomized controlled trials; VAS, visual analog scale.

for NP therapy and provide clinical evidence for the selection of PRF modes in clinical practice via synthesising RCTs in journal publications. This study has some limitations. The sample size of the eligible RCTs might not be large and the accuracy of our research conclusions might be biased due to language limitations, as we will only include studies published in English. Overall, the study findings will provide comprehensive information for future study designs in terms of interventional treatment of NP.

**Author affiliations**
[1]Department of Anesthesiology, Xuanwu Hospital Capital Medical University, Beijing, China
[2]Department of General Surgery, Xuanwu Hospital Capital Medical University, Beijing, China
[3]Department of Thoracic Surgery, Xuanwu Hospital Capital Medical University, Beijing, China
[4]Xuanwu Hospital, Capital Medical University, Beijing, China

**Acknowledgements** The authors would like to thank the participants of the study for their cooperation.

**Contributors** YJ, ZW, TeW and TiW made substantial contributions to clinical study design. YJ, YM and GF made substantial contributions to manuscript preparation, editing and review. KF made contributions to English language editing. YM, KF and GF consulted about clinical issues. YJ, YM, TeW and TiW have given final approval of the version to be published. YJ, ZW and YM contributed equally to this work. TiW is responsible as corresponding author.

**Funding** This study was funded and sponsored by Beijing Municipal Medical Science Institute-Public Welfare Development Reform Pilot Project (Capital Medical Research No. 2019-2).

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.



**ORCID iDs**
Yitong Jia http://orcid.org/0000-0002-3872-9038
Zheng Wang http://orcid.org/0000-0001-6262-2102

## REFERENCES

1 Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. *Lancet Neurol* 2010;9:807–19.
2 van Hecke O, Austin SK, Khan RA, *et al*. Neuropathic pain in the general population: a systematic review of epidemiological studies. *Pain* 2014;155:654–62.
3 Colloca L, Ludman T, Bouhassira D, *et al*. Neuropathic pain. *Nat Rev Dis Primers* 2017;3:17002.
4 Park CH, Lee SH, Lee PB. Intradiscal pulsed radiofrequency application duration effect on lumbar discogenic low back pain. *Pain Physician* 2020;23:E535–40.
5 Martin DC, Willis ML, Mullinax LA, *et al*. Pulsed radiofrequency application in the treatment of chronic pain. *Pain Pract* 2007;7:31–5.
6 Kim K, Jo D, Kim E. Pulsed radiofrequency to the dorsal root ganglion in acute herpes zoster and postherpetic neuralgia. *Pain Physician* 2017;20:E411–8.
7 Shi Y, Wu W. Treatment of neuropathic pain using pulsed radiofrequency: a meta-analysis. *Pain Physician* 2016;19:429–44.
8 Jia Y, Shrestha N, Wang X, *et al*. The long-term outcome of CT-guided pulsed radiofrequency in the treatment of idiopathic glossopharyngeal neuralgia: a retrospective multi-center case series. *J Pain Res* 2020;13:2093–102.
9 Vuka I, Marciuš T, Došenović S, *et al*. Efficacy and safety of pulsed radiofrequency as a method of dorsal root ganglia stimulation in patients with neuropathic pain: a systematic review. *Pain Med* 2020;21:3320–43.
10 Ren H, Zhao C, Wang X, *et al*. The efficacy and safety of the application of pulsed radiofrequency, combined with low-temperature continuous radiofrequency, to the gasserian ganglion for the treatment of primary trigeminal neuralgia: study protocol for a prospective, open-label, Parall. *Pain Physician* 2021;24:89–97.
11 Contreras Lopez WO, Navarro PA, Vargas MD, *et al*. Pulsed radiofrequency versus continuous radiofrequency for facet joint low back pain: a systematic review. *World Neurosurg* 2019;122:390–6.
12 Wu C-Y, Lin H-C, Chen S-F, *et al*. Efficacy of pulsed radiofrequency in herpetic neuralgia: a meta-analysis of randomized controlled trials. *Clin J Pain* 2020;36:887–95.
13 Wu H, Zhou J, Chen J, *et al*. Therapeutic efficacy and safety of radiofrequency ablation for the treatment of trigeminal neuralgia: a systematic review and meta-analysis. *J Pain Res* 2019;12:423–41.
14 Li H, Ding Y, Zhu Y, *et al*. Effective treatment of postherpetic neuralgia at the first branch of the trigeminal nerve by high-voltage pulsed radiofrequency. *Front Neurol* 2021;12:746035.
15 Sam J, Catapano M, Sahni S, *et al*. Pulsed Radiofrequency in Interventional Pain Management: Cellular and Molecular Mechanisms of Action - An Update and Review. *Pain Physician* 2021;24:525–32.
16 Vanneste T, Van Lantschoot A, Van Boxem K, *et al*. Pulsed radiofrequency in chronic pain. *Curr Opin Anaesthesiol* 2017;30:577–82.
17 Teixeira A, Sluijter ME. Intradiscal high-voltage, long-duration pulsed radiofrequency for discogenic pain: a preliminary report. *Pain Med* 2006;7:424–8.
18 Luo F, Meng L, Wang T, *et al*. Pulsed radiofrequency treatment for idiopathic trigeminal neuralgia: a retrospective analysis of the causes for ineffective pain relief. *Eur J Pain* 2013;17:1189–92.
19 Fang L, Tao W, Jingjing L, *et al*. Comparison of High-voltage- with Standard-voltage pulsed radiofrequency of gasserian ganglion in the treatment of idiopathic trigeminal neuralgia. *Pain Pract* 2015;15:595–603.
20 Luo F, Wang T, Shen Y, *et al*. High voltage pulsed radiofrequency for the treatment of refractory neuralgia of the infraorbital nerve: a prospective double-blinded randomized controlled study. *Pain Physician* 2017;20:271–9.
21 Fang L, Jia Z. In Response to Comments on "Long-term Follow-up of Pulsed Radiofrequency Treatment for Trigeminal Neuralgia: Kaplan-Meier Analysis in a Consecutive Series of 149 Patients". *Pain Physician* 2022;25:E409.
22 Silva V. Comments on "Long-term Follow-up of Pulsed Radiofrequency Treatment for Trigeminal Neuralgia: Kaplan-Meier Analysis in a Consecutive Series of 149 Patients". *Pain Physician* 2022;25:E408.
23 Zipu J, Hao R, Chunmei Z, *et al*. Long-Term follow-up of pulsed radiofrequency treatment for trigeminal neuralgia: Kaplan-Meier analysis in a consecutive series of 149 patients. *Pain Physician* 2021;24:E1263–71.
24 Wan C-F, Song T. Comparison of two different pulsed radiofrequency modes for prevention of postherpetic neuralgia in elderly patients with Acute/Subacute trigeminal herpes zoster. *Neuromodulation* 2021. doi:10.1111/ner.13457. [Epub ahead of print: 18 May 2021] (published Online First: 2021/05/20).
25 Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2016;354:i4086.

26 Cumpston M, Li T, Page MJ, *et al*. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for systematic reviews of interventions. *Cochrane Database Syst Rev* 2019;10:Ed000142.
27 Ochoa JL. Neuropathic pain: redefinition and a grading system for clinical and research purposes. *Neurology* 2009;72:1282–3.
28 Brazier JE, Harper R, Jones NM, *et al*. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. *BMJ* 1992;305:160–4.
29 McGowan J, Sampson M, Salzwedel DM, *et al*. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *J Clin Epidemiol* 2016;75:40–6.
30 Huang X, Lin J, Demner-Fushman D. Evaluation of PICO as a knowledge representation for clinical questions. *AMIA Annu Symp Proc* 2006;2006:359–63.
31 Guyatt G, Oxman AD, Akl EA, *et al*. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;64:383–94.
32 Wan X, Wang W, Liu J, *et al*. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014;14:135.
33 Shi J, Luo D, Wan X. Detecting the skewness of data from the sample size and the five-number summary 2020.
34 Egger M, Davey Smith G, Schneider M, *et al*. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
35 Sterne JAC, Sutton AJ, Ioannidis JPA, *et al*. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;343:d4002.

**Supplement 1.** PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

| Section and topic | Item No | Checklist item | Page No |
|---|---|---|---|
| **ADMINISTRATIVE INFORMATION** | | | |
| Title: | | | |
| Identification | 1a | Identify the report as a protocol of a systematic review | 1 |
| Update | 1b | If the protocol is for an update of a previous systematic review, identify as such | n/a |
| Registration | 2 | If registered, provide the name of the registry (such as PROSPERO) and registration number | 2 |
| Authors: | | | |
| Contact | 3a | Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author | 1 |
| Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review | 11 |
| Amendments | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | n/a |
| Support: | | | |
| Sources | 5a | Indicate sources of financial or other support for the review | 11 |
| Sponsor | 5b | Provide name for the review funder and/or sponsor | 11 |
| Role of sponsor or funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | 11 |

| | | | |
|---|---|---|---|
| **INTRODUCTION** | | | |
| Rationale | 6 | Describe the rationale for the review in the context of what is already known | 3 |
| Objectives | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | 3-4 |
| **METHODS** | | | |
| Eligibility criteria | 8 | Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review | 5 |
| Information sources | 9 | Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage | 6-7 |
| Search strategy | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | 6-7 |
| Study records: | | | |
| Data management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | 7 |
| Selection process | 11b | State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) | 7 |
| Data collection process | 11c | Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | 7 |
| Data items | 12 | List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications | 9 |
| Outcomes and prioritization | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | 6 |

| | | | |
|---|---|---|---|
| Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | 8 |
| Data synthesis | 15a | Describe criteria under which study data will be quantitatively synthesized | 9 |
| | 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$, Kendall's $\tau$) | 9 |
| | 15c | Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) | 9 |
| | 15d | If quantitative synthesis is not appropriate, describe the type of summary planned | 9 |
| Meta-bias(es) | 16 | Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) | 8 |
| Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (such as GRADE) | 8 |

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

*From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.*

| Search step | Search terms |
|---|---|
| #1 | "neuralgia"[MeSH Terms] OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR "neuralgias"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("neuropathic"[All Fields] AND "pain"[All Fields]) OR "neuropathic pain"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("neuropathic"[All Fields] AND "pains"[All Fields]) OR "neuropathic pains"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("pain"[All Fields] AND "neuropathic"[All Fields]) OR "pain neuropathic"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("pains"[All Fields] AND "neuropathic"[All Fields]) OR "pains neuropathic"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR "neurodynia"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("neuralgia"[All Fields] AND "atypical"[All Fields]) OR "neuralgia atypical"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("atypical"[All Fields] AND "neuralgia"[All Fields]) OR "atypical neuralgia"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("atypical"[All Fields] AND "neuralgias"[All Fields]) OR "atypical neuralgias"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("neuralgias"[All Fields] AND "atypical"[All Fields]) OR "neuralgias atypical"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("neuralgia"[All Fields] AND "iliohypogastric"[All Fields] AND "nerve"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("iliohypogastric"[All Fields] AND "nerve"[All Fields] AND "neuralgia"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("iliohypogastric"[All Fields] AND "nerve"[All Fields] AND "neuralgias"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("nerve"[All Fields] AND "neuralgia"[All Fields] AND "iliohypogastric"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("nerve"[All Fields] AND "neuralgias"[All Fields] AND "iliohypogastric"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("neuralgias"[All Fields] AND "iliohypogastric"[All Fields] AND "nerve"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("paroxysmal"[All Fields] AND "nerve"[All Fields] AND "pain"[All Fields]) OR "paroxysmal nerve pain"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("nerve"[All Fields] AND "pain"[All Fields] AND "paroxysmal"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("nerve"[All Fields] AND "pains"[All Fields] AND "paroxysmal"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("pain"[All Fields] AND "paroxysmal"[All Fields] AND "nerve"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("pains"[All Fields] AND "paroxysmal"[All Fields] AND "nerve"[All Fields])) OR |

| | |
|---|---|
| | ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("paroxysmal"[All Fields] AND "nerve"[All Fields] AND "pains"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("neuralgia"[All Fields] AND "perineal"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("neuralgias"[All Fields] AND "perineal"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("perineal"[All Fields] AND "neuralgia"[All Fields]) OR "perineal neuralgia"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("perineal"[All Fields] AND "neuralgias"[All Fields]) OR "perineal neuralgias"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("neuralgia"[All Fields] AND "stump"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("neuralgias"[All Fields] AND "stump"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("stump"[All Fields] AND "neuralgia"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("stump"[All Fields] AND "neuralgias"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("neuralgia"[All Fields] AND "supraorbital"[All Fields]) OR "neuralgia supraorbital"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("neuralgias"[All Fields] AND "supraorbital"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("supraorbital"[All Fields] AND "neuralgia"[All Fields]) OR "supraorbital neuralgia"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("supraorbital"[All Fields] AND "neuralgias"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("neuralgia"[All Fields] AND "vidian"[All Fields]) OR "neuralgia vidian"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("neuralgias"[All Fields] AND "vidian"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("vidian"[All Fields] AND "neuralgia"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("vidian"[All Fields] AND "neuralgias"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("nerve"[All Fields] AND "pain"[All Fields]) OR "nerve pain"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("nerve"[All Fields] AND "pains"[All Fields]) OR "nerve pains"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("pain"[All Fields] AND "nerve"[All Fields]) OR "pain nerve"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("pains"[All Fields] AND "nerve"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("neuralgia"[All Fields] AND "ilioinguinal"[All Fields])) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("ilioinguinal"[All Fields] AND "neuralgia"[All Fields]) OR "ilioinguinal neuralgia"[All Fields]) OR ("neuralgia"[MeSH Terms] OR "neuralgia"[All Fields] OR ("ilioinguinal"[All Fields] AND "neuralgias"[All Fields]) OR "ilioinguinal neuralgias"[All Fields]) OR ("neuralgia"[MeSH |

| | |
|---|---|
| | Terms] OR "neuralgia"[All Fields] OR ("neuralgias"[All Fields] AND "ilioinguinal"[All Fields])) |
| #2 | "pulsed radiofrequency treatment"[MeSH Terms] OR "pulsed radiofrequency treatments"[All Fields] OR (("radiofrequencies"[All Fields] OR "Radiofrequency"[All Fields] OR "radiofrequent"[All Fields]) AND "treatment pulsed"[All Fields]) OR (("radiofrequencies"[All Fields] OR "Radiofrequency"[All Fields] OR "radiofrequent"[All Fields]) AND "treatments pulsed"[All Fields]) OR "treatment pulsed radiofrequency"[All Fields] OR "treatments pulsed radiofrequency"[All Fields] OR "pulsed radio frequency treatment"[All Fields] |
| #3 | (clinical[tiab] AND trial[tiab]) OR "clinical trials as topic"[mesh] OR "clinical trial"[pt] OR random*[tiab] OR "random allocation"[mesh] OR "therapeutic use"[sh] |
| #4 | #1 AND #2 AND #3 |